Strategies in MS Treatment: Striving for NEDA (No evidence of disease activity)

Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Strategies in MS Treatment: Striving for NEDA (No Evidence of Disease Activity)

Strategies in MS Treatment: Striving for NEDA (No Evidence of Disease Activity)
Review benefit and risk strategies for selecting therapy for MS patients, and explore emergent treatment options to improve patient adherence.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This interactive educational module, will review the positive and negative considerations when treating of MS patients, including strategies for improved patient adherence and achieving NEDA.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 


    Prof. Dr. med. Andrew Chan

    Prof. Chan has disclosed that he is an intellectual property rights/patent holder of Antibodyprofile and Protagen. He receives consulting fees from Bayer, Biogen, Genzyme, Roche and Novartis; fees for non-CME services from Roche and Teva; and contracted research fees from Biogen, Genyzme and Novartis. 


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose
    • Ann Early has nothing to disclose.
    • Gavin Giovannoni, MBBCh, PhD, FCP (S.A., Neurol), FRCP, FRCPath  has disclosed he is on the steering committee for AbbVie, Biogen-Idec, Novartis, TEVA, Roche; a consultant for Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals; and a clinical advisor to Canbex.
    • John D. Hixson, MD has disclosed he is contracted researcher for UCB Inc.
    • Michael B. Montalto, PhD has nothing to disclose.
    • Lawrence Sherman has nothing to disclose. 
  • Learning Objectives

    By the end of this module, you will be able to:

    • Assess the importance of early diagnosis and treatment to slow down MS progression
    • Compare and contrast benefits and risks of currently approved treatment agents
    • Evaluate current and future treatment options based on a goal of no evidence of disease activity (NEDA) 
  • Target Audience

    This activity is designed to meet the educational needs of practicing neurologists, and other healthcare professionals that treat patients with multiple sclerosis.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Global Neurology Academy you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.